Kenya Launches Revolutionary Twice-Yearly HIV Prevention Shot

A single injection that prevents HIV for six months is now available in Kenya, offering new hope in the fight against a disease that has affected millions of families across the country.

Kenya launched Lenacapavir, a long-acting HIV prevention medication, on February 26, 2026, at Riruta Health Center. The country will receive 58,000 doses this year, making it one of ten nations worldwide to offer this American-made innovation to its citizens.

The timing couldn't be more critical. While Kenya has made substantial progress fighting HIV, young people and women still face heightened risk of infection. Daily prevention pills work, but many people struggle to take medication every single day. A shot that lasts half a year changes everything.

Dr. Jennifer Galbraith from the U.S. Centers for Disease Control and Prevention emphasized that this isn't just about convenience. It's about giving people real control over their health and accelerating the end of the epidemic. The medication gives discreet, effective protection without the daily burden of pills.

American company Gilead Sciences developed the drug, which patients in the United States have used since June 2025. After seeing its success, the U.S. government partnered with Gilead to extend access to up to two million people in countries with high HIV rates. The Global Fund is providing 33,000 doses to Kenya, while the U.S. government procured an additional 25,000 doses, expected to arrive by August 2026.

The Ripple Effect goes far beyond individual protection. When communities reduce new HIV infections, they strengthen their entire health systems and economic stability. Controlling epidemics protects supply chains, enables families to thrive, and prevents localized outbreaks from becoming regional crises.

Kenya's willingness to quickly adopt evidence-based prevention tools demonstrates the leadership that has defined its 60-year partnership with the United States. This launch builds on decades of collaboration that has saved millions of lives through focused health assistance and sustainable, country-led solutions.

The early rollout in Kenya helps establish a sustainable market that will eventually lead to broader manufacturing, lower costs, and long-term access for more countries. As more manufacturers enter the space and competition grows, the life-saving innovation becomes a permanent fixture of national health systems rather than a temporary donation.

Success will be measured in the numbers that matter most: fewer new infections, families protected, and young people with the tools to control their own futures.